Cancer-targeting gene therapy using tropism-modified adenovirus

Anticancer Research

Volumn 27, Issue 6 A, 2007, Pages 3679-3684

  Tanaka, Toshihiro ^a   Kuroki, Motomu ^a   Hamada, Hirofumi ^b   Kato, Kazunori ^b   Kinugasa, Tetsushi ^a   Shibaguchi, Hirotomo ^a   Zhao, Jun ^a   Kuroki, Masahide ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus; Gene therapy; Review; Targeting

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GENE THERAPY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; COLON CANCER; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG SENSITIVITY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOVIRIDAE; ANIMALS; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LIGANDS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, VIRUS; TROPISM;

EID: 35348977671     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Smith AE: Viral vectors in gene therapy. Ann Rev Microbiol 49: 807-838, 1995.
2. Brody SL and Crystal RG: Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 716: 90-101; discussion 101-103, 1994.
3. Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T and Ikeda S: Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther 11: 431-440, 2004.
4. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H and Hamada H: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10: 162-171, 2004.
5. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ and Roth JA: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58: 2288-2292, 1998.
6. Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA and Cristiano RJ: In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 16: 3415-3422, 1996.
7. Zhang WW, Fang X, Mazur W, French BA, Georges RN and Roth JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1: 5-13, 1994.
8. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ and Russell PJ: In vivo gene transfer for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivery by identical adenovirus vectors. Hum Gene Ther 9: 1617-1626, 1998.
9. Staba M-J, Mauceri HJ, Kufe DW, Hallahan DE and Weichselbaum RR: Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 5: 293-300, 1998.
10. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF and Chiang YL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer specific gene expression. Cancer Res 55: 5283-5287, 1995.
11. Kanai F, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y, Saito I, Nakabayashi H, Tamaoki T, Tanaka T, Lan KH, Kato N, Shiina S and Omata M: Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the Herpes simplex virus thymidine kinase gene. Hepatology 23: 1359-1368, 1996.
12. Ohashi M, Kanai F, Ueno H, Tanaka T, Tateishi K, Kawakami T, Koike Y, Ikenoue T, Shiratori Y, Hamada H and Omata M: Adenovirus-mediated p53 tumor suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut 44: 366-371, 1999.
13. Atienza C Jr, Elliott MJ, Dong YB, Yang HL, Stilwell A, Liu TJ and McMasters KM: Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Int J Mol Med 6: 55-63, 2000.
14. Zhang Y, Yu D, Xia W and Hung MC: HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 18: 1947-1954, 1995.
15. Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H and Kazumaki N: Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N117Y. Int J Cancer 78: 366-371, 1998.
16. Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T and Yamagishi H: Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res 25: 3847-3854, 2005.
17. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL and Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997.
18. Tomko RP, Xu R and Philipson L: HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356, 1997.
19. Hong SS, Karayan L, Tournier J, Curiel DT and Boulanger PA: Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 16: 2294-2306, 1997.
20. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319, 1993.
21. Harris JD and Lemoine NR: Strategies for targeted gene therapy. Trends Genet 12: 400-405, 1996.
22. McDonald GA, Zhu G, Li Y, Kovesdi I, Wickham TJ and Sukhatme VP: Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J Gene Med 1: 103-110, 1999.
23. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, Kohama G and Hamada H: Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 10: 75-85, 2003.
24. Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y and Hayakawa T: Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 5: 267-276, 2003.
25. Alemany R and Curiel DT: CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347-1353, 2001.
26. Leissner P, Legrand V, Schlesinger Y, Hadji DA, Raaij M van, Cusack S, Pavirani A and Mehtali M: Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 8: 49-57, 2001.
27. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P and Vigne E: Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 8: 485-494, 2003.
28. Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M and Stevenson SC: In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 5: 770-779, 2002.
29. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, Nemerow GR, Kaleko M and Stevenson SC: Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 14: 777-787, 2003.
30. Shayakhmetov DM, Li ZY, Ni S and Lieber A: Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 62: 1063-1068, 2002.
31. Gaggar A, Shayakhmetov D and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412, 2003.
32. Segerman A, Arnberg N, Erikson A, Lindman K and Wadell G: There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species of B2 adenoviruses. J Virol 77: 1157-1162, 2003.
33. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77: 9183-9191, 2003.
34. Kinugasa N, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Ishizaki M Toshikuni N, Yoshida K, Uematsu S and Tsuji T: Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer 80: 1820-1825, 1999.
35. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG and Kaul A: Expression of complement regulatory proteins - CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 76: 176-182, 2000.
36. Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123, 2003.
37. Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, Sova P, Morihara J, Feng Q, Kiviat N, Toure P, Sow PS and Lieber A: Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 13: 1072-1081, 2006.
38. Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF and Horvat B: Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 3: 659-666, 2002
39. Seshidhar Reddya P, Ganesha S, Limbacha MP, Branna T, Pinkstaffa A, Kalossa M, Kalekoa M and Connelly S: Development of adenovirus serotype 35 as a gene transfer vector. Virology 311: 384-393, 2003
40. Shayakhmetov DM and Lieber A: Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 74: 10274-10286, 2000.
41. Vigne E, Dedieu JF, Brie A, Gillardeaux A, Briot D, Benihoud K, Latta-Mahieu M, Saulnier P, Perricaudet M and Yeh P: Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther 10: 153-162, 2003.
42. Wu E, Pache L, Von Seggern DJ, MullenTM, Mikyas Y, Stewart PL and Nemerow GR: Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol 77: 7225-7235, 2003.
43. Nakamura T, Sato K and Hamada H: Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 77: 2512-2521, 2003.
44. Haisma HJ, Pinedo HM, van Rijswijk A, van der Muelen-Muileman I, Sosnowski BA, Ying W, van Beusechem VW, Tillman BW, Gerritsen WR and Curiel DT: Tumor-specific gene transfer via an adenoviral vector targeted to the pancarcinoma antigen EpCAM. Gene Ther 6: 1469-1474, 1999.
45. Heideman DA, Snijders PJ, Craanen ME, Bloemena E, Meijer CJ, Meuwissen SG, van Beusechem VW, Pinedo HM, Curiel DT, Haisma HJ and Gerritsen WR: Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 8: 342-351, 2001.
46. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R and Kontermann RE: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 3: 882-891, 2001.
47. Kashentseva EA, Seki T, Curiel DT and Dmitriev IP: Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 62: 609-616, 2002.
48. Tanaka T, Huang J, Hirai S, Kuroki Mo, Kuroki Ma, Watanabe N, Tomihara K, Kato K and Hamada H: Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 12: 3803-3813, 2006.
49. Volpers C, Thirion C, Biermann V, Hussmann S, Kewes H, Dunant P, von der Mark H, Herrmann A, Kochanek S and Lochmuller H: Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 77: 2093-2104, 2003.
50. Henning P, Magnusson MK, Gunneriusson E, Hong SS, Boulanger P, Nygren PA and Lindholm L: Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 13: 1427-1439, 2002.